Does the Vera Therapeutics (VERA) CEO report any indirect share ownership?

The filing reports indirect ownership of 99,081 shares of Class A common stock held by a trust and 122,949 shares held by a GRAT. These entries are labeled as holdings, showing the number of shares attributed to each entity after the reported transactions on May 12, 2026.

Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics, Inc. president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A common stock on May 12, 2026. The shares were sold in two tranches of 4,281 shares at a weighted-average price of $37.0868 and 14,219 shares at a weighted-average price of $36.6396, with actual prices ranging from $35.96 to $37.15. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on January 9, 2026. The filing also reports indirect holdings through a trust and a GRAT, which together hold more than 200,000 shares after these transactions.

Insider Trade Summary 10b5-1

Net Seller: 18,500 shares ($679,747)

Net Sell 4 txns

Insider Fordyce Marshall

Role PRESIDENT AND CEO

Sold 18,500 shs ($680K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	14,219	$36.6396	$521K
Sale	Class A Common Stock	4,281	$37.0868	$159K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 221,025 shares (Direct, null); Class A Common Stock — 122,949 shares (Indirect, By GRAT)

Footnotes (1)

This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold (first tranche): 4,281 shares Price (first tranche): $37.0868 per share Shares sold (second tranche): 14,219 shares +4 more

7 metrics

Shares sold (first tranche) 4,281 shares Open-market sale of Class A common stock on May 12, 2026 at weighted-average $37.0868

Price (first tranche) $37.0868 per share Weighted-average sale price for 4,281-share transaction

Shares sold (second tranche) 14,219 shares Open-market sale of Class A common stock on May 12, 2026 at weighted-average $36.6396

Price (second tranche) $36.6396 per share Weighted-average sale price for 14,219-share transaction

Total net shares sold 18,500 shares Net open-market sales reported across two non-derivative transactions

Trust holdings after transaction 99,081 shares Indirect Class A common stock ownership by trust after May 12, 2026

GRAT holdings after transaction 122,949 shares Indirect Class A common stock ownership by GRAT after May 12, 2026

Key Terms

Rule 10b5-1(c), weighted-average price, GRAT, open-market sale

4 terms

Rule 10b5-1(c) regulatory

"a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted-average price financial

"The price reported is a weighted-average price. These shares were sold in multiple transactions"

GRAT financial

"total_shares_following_transaction: 122949.0000, direct_or_indirect: I, nature_of_ownership: By GRAT"

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 04:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fordyce Marshall

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	05/12/2026		S⁽¹⁾		14,219	D	$36.6396⁽²⁾	221,025	D
Class A Common Stock	05/12/2026		S⁽¹⁾		4,281	D	$37.0868⁽³⁾	216,744	D
Class A Common Stock								122,949	I	By GRAT
Class A Common Stock								99,081	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	/s/ Joseph R. Young, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vera Therapeutics (VERA) report for Marshall Fordyce?

Vera Therapeutics reported that president and CEO Marshall Fordyce sold 18,500 shares of Class A common stock in open-market transactions. The trades occurred on May 12, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in January 2026.

At what prices did the Vera Therapeutics (VERA) CEO sell shares?

Marshall Fordyce sold 4,281 shares at a weighted-average price of $37.0868 and 14,219 shares at $36.6396. Footnotes state the actual sale prices ranged from $35.96 to $37.15 across multiple trades, with full breakdowns available on request from the company or regulators.

How many Vera Therapeutics (VERA) shares did the CEO sell in total?

The Form 4 shows Marshall Fordyce sold a total of 18,500 shares of Vera Therapeutics Class A common stock. These consisted of two separate open-market sale entries on the same date, one for 4,281 shares and another for 14,219 shares, both reported as non-derivative transactions.

Were the Vera Therapeutics (VERA) CEO’s stock sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the sales were made under a written trading plan adopted on January 9, 2026, that meets Rule 10b5-1(c) requirements. Such plans schedule trades in advance, helping separate routine portfolio management from discretionary market-timing decisions.

What type of security did the Vera Therapeutics (VERA) insider transactions involve?

All reported transactions involve Vera Therapeutics Class A common stock as non-derivative securities. The Form 4 does not list any option, warrant, or other derivative exercises in this filing, and the derivative position summary shows no derivative transactions for the reported period.